Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Launched by NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD) · Aug 21, 2001
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
Nonsyndromic hereditary hearing impairment is a genetically heterogeneous disorder that can be caused by mutations in any one of at least 60 different genes. Enlargement of the vestibular aqueduct (EVA) is a radiologic finding known to be associated with mutations in one of these genes, the Pendred syndrome gene (SLC26A4, formerly known as PDS). EVA may thus serve as a clinically useful marker to facilitate the diagnosis of hearing impairment. Recent data from our laboratory and others indicates that only a subset of individuals with EVA have SLC26A4 mutations, and therefore some EVA cases ...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • Subjects must have or be a family member of a participant with known or non-syndromic SNHL associated with EVA or have evidence of other findings that suggest that EVA might be part of a novel phenotype
- • There must be at least two participating affected family members with one exception: if there is only one participating affected family member, there must be genetic test results identifying only one pathogenic mutant allele of SLC26A4
- • Adults must be able to provide informed consent
- • Minors must have a parent or guardian able to provide consent
- • Age between 0-99.
- EXCLUSION CRITERIA:
- • Subjects with known exposure to physical or chemical teratogens in utero that could account for their inner ear malformations such as thalidomide or radiation
- • Any hearing loss that is associated with symptoms which meet the criteria of already known syndromes, such as, branchio-oto-renal (BOR) syndrome, which comprises system malformations and branchial cleft abnormalities and is caused by heterozygous mutations in the EYA1 gene.
- • Previous genetic testing identifying two pathogenic mutant alleles of SLC26A4.
- • Prospective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled.
About National Institute On Deafness And Other Communication Disorders (Nidcd)
The National Institute on Deafness and Other Communication Disorders (NIDCD) is a prominent agency within the National Institutes of Health (NIH) dedicated to advancing research and understanding of hearing, balance, taste, smell, voice, speech, and language disorders. Through rigorous clinical trials and innovative research initiatives, the NIDCD aims to improve the diagnosis, treatment, and prevention of communication disorders, ultimately enhancing the quality of life for individuals affected by these conditions. The institute fosters collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical practices and public health strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Bethesda, Maryland, United States
Patients applied
Trial Officials
Thomas B Friedman, Ph.D.
Principal Investigator
National Institute on Deafness and Other Communication Disorders (NIDCD)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials